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Prostate cancer (PCa) is a major serious malignant tumor and is commonly diagnosed
in older men. Identification of novel cancer-related genes in PCa is important for
understanding its tumorigenesis mechanism and developing new therapies against PCa.
Here, we used RNA sequencing to identify the specific genes, which are upregulated in
PCa cell lines and tissues. The cell division cycle associated protein (CDCA) family, which
plays a critical role in cell division and proliferation, is upregulated in the PCa cell lines of
our RNA-Sequencing data. Moreover, we found that CDCA2 is overexpressed, and its
protein level positively correlates with its histological grade, clinical stage, and Gleason
Score. CDCA2 was further found to be upregulated and correlated with poor prognosis
and patient survival in multiple cancer types in The Cancer Genome Atlas (TCGA) dataset.
The functional study suggests that inhibition of CDCA2 will lead to apoptosis and lower
proliferation in vitro. Silencing of CDCA2 also repressed tumor growth in vivo. Loss of
CDCA2 affects several oncogenic pathways, including MAPK signaling. In addition, we
further demonstrated that CDCA2 was induced in hypoxia and directly regulated by the
HIF-1α/Smad3 complex. Thus, our data indicate that CDCA2 could act as an oncogene
and is regulated by hypoxia and the HIF-1αpathway. CDCA2may be a useful prognostic
biomarker and potential therapeutic target for PCa.
Keywords: CDCA2, prostate cancer, apoptosis, proliferation, HIF-1a
INTRODUCTION
In the United States, prostate cancer (PCa) is the second leading cause of cancer death in men.
In 2017 in the United States, about 161,360 people were diagnosed as PCa, and, of these, 26,730
PCa patients died (1). Although the treatment has made significant progress, around one third of
organ-confined PCa patients who underwent surgical treatment would progressed to aggressive
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or metastatic PCa within 10 years (2). Thus, it is important
to elucidate the PCa tumorigenic mechanism by investigating
PCa-related genes, which will help provide better therapeutic
strategies for treatment.
Increasing lines of evidence have suggested that cell
division cycle associated proteins (CDCA) are critical in tumor
progression. CDCA1 is a promising prognostic tissue biomarker
in oral cavity cancer (3). Overexpression of CDCA2 and CDCA3
is a frequent event for oral squamous cell carcinomas (OSCC).
Their overexpression would prevent G1 arrest through repressing
cyclin-dependent kinase inhibitors and inducing apoptosis (4, 5).
CDCA4 enhances proliferation and reduces the cellular apoptotic
rate in human breast cancer MCF-7/ADM cells (6). CDCA5is
overexpressed and functions as an oncogene in bladder cancer,
hepatocellular carcinoma, and gastric cancer (7–9). In addition,
CDCA3 and CDCA5 mRNA expression levels are significantly
elevated in breast tumor samples or breast cancer cells compared
with normal controls (10). So far, the expression and role of the
CDCA family in the prostate is not sufficiently studied.
Pathological hypoxia is critical in the process of cancer
progression and dissemination, and it also affects both tumor
microenvironment and cancer cells. In addition, hypoxia also
plays a vital role in epithelial to mesenchymal transition
(EMT)-like cancer cell migration and drug resistance (11).
In hypoxic condition, several pathways, including HIF, PI3K,
MAPK, and NFκB pathways, will interact with each other,
lead positive and negative feedback loops, and will strengthen
or attenuate hypoxic effects (11). Hypoxic conditions in PCa
are associated with poor prognosis (12, 13). Under hypoxia
stimulation, genes induced by HIF, PI3K, MAPK, or NFκB
pathways may contribute to the cancer prognosis. For example,
choline kinase (Chk) contributes to malignant transformation
and progression of prostate cancer and is controlled by
HIF-1α signaling (14). In prostate cancer, the HIF-1α is
expression regulator of S100A8/A9, which play important
roles during tumorigenesis, affecting inflammatory processes,
proliferation, invasion, and metastasis of tumor cells (15).
HIF-1α also directly regulates BCL-xL, which is a hypoxia-
responsive, anti-apoptotic protein of the Bcl-2 family and is also
overexpressed in prostate carcinoma and many other cancers
(16). In some conditions, HIF-1α can directly interact with
Smad3 and synergistically regulate hypoxia targets expression
(17, 18).
Of interest, we found that majority of the genes encoding
for the CDCA family were upregulated in PCa, as confirmed by
RNA sequencing data. Among this family, CDCA2, also named
as Repo-Man (Recruits PP1 onto Mitotic chromatinat anaphase),
is a nuclear protein that binds to protein phosphatase 1 γ (PP1γ).
CDCA2 is responsible for the targeting of PP1 to chromatin
during anaphase, leading to the dephosphorylation of H3 and
controls cell proliferation in vitro (19, 20). But its function in
cancer, especially in prostate cancer, is not well defined. In this
study, we chose CDCA2 to further investigate its function in PCa.
Our result suggests that CDCA2 was overexpressed in PCa and
many other cancer types. It functions as an oncogene in PCa, as
confirmed in both in vitro and in vivo studies. We also found
CDCA2 is induced in hypoxia condition and directly regulated
byHIF-1α. This genemay represent a novel and useful prognostic
biomarker and therapeutic biomarker for PCa.
MATERIALS AND METHODS
Cell Culture and Transfection
A series of PCa cell lines (LAPC4, 22RV1, LNCap, Du145, and
PC3) were used in this study. In brief, PCa cell lines were
maintained in RPMI 1640 medium (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum (FBS), 1% penicillin-
streptomycin (10 ng/ml penicillin and 10 U/ml streptomycin),
and 2.5mM glutamine at 37◦C in a humidified 5% CO2
incubator. Control siRNA (siControl) and CDCA2 short
interfering RNA (siCDCA2), which were ordered from Santa
Cruz Biotechnology (Dallas, TX, USA), were transfected with an
RNAiMAX transfection reagent (Invitrogen, Eugene, OR, USA).
RNA Sequencing
RNAeasy Mini kit (QIAGEN) was used for high quality RNA
extraction. Normal prostate RNA was purchased from Clontech
(Clontech, Palo Alto, CA). An RNA Sequencing library was
prepared according to the KAPA biosystems’ manual. The
prepared libraries were analyzed by Illumina HiSeq platform.
The RNA sequencing reads were analyzed by using the standard
protocol as previously reported (21).
Reverse Transcription and Quantitative
Real-Time PCR
Reverse transcription was performed according to manual
of manufacturers (Invitrogen, Eugene, OR, USA). In brief,
1 µg of RNA was used for each reverse transcription
reaction. Quantitative real-time PCR was carried out with
SYBR Green master mix in Applied Biosystems 7,300 Real-
time systems. All Real-time PCR primers used are listed in
Supplemental Table 1 Each experiment was performed in three
independent experiments.
Cell Proliferation Assay
Du145 and PC3 cells were used for growth curve study. In brief,
cells were seeded in six-well plates at an appropriate density
without penicillin/streptomycin. After 16-h, cells were then
transfected with siControlor CDCA2 siRNA, respectively. Then
cells were trypsinized and collected for cell number counting at
0-, 24-, and 48-h time points after transfection. Each experiment
was repeated at least three times.
Apoptosis Assay
PE Annexin V Apoptosis Detection Kit I (BD Bioscience) was
used for apoptotic cells detection by flow cytometry. About 48-h
after transfection, cells were harvested and rinsed with cold PBS
once. Then cells were suspended in a binding buffer, and about
1 × 105cells were used for staining with PE Annexin V and 7-
AAD. After 15-min incubation at room temperature in the dark,
stained cells were then analyzed by flow cytometry. The apoptotic
percentage was calculated as the sum of early apoptotic cells and
late apoptotic cells. Each experiment was conducted in triplicate
in three independent experiments.
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FIGURE 1 | The cell division cycle associated protein (CDCA) family is increased in prostate cancer. (A) Heatmap of RNA sequencing results of a series of prostate
cancer cells and normal prostate tissue. (B–F) Real-time PCR for validation of RAN-sequencing results for CDCA1 (B), CDCA2 (C), CDCA3 (D), CDCA4, and CDCA5
(F). All the data are shown as mean ± SD. **P < 0.01.
Construction of CDCA2 Knock-Down
Stable Cell Lines
The lenti-virus coding for short-hairpins RNA (shRNA) targeting
the CDCA2 region (5’-GUCUGUGGCAAGAGGGAAA-3’) was
obtained from GENECHEM (Shanghai, China). A total of
1 × 105 Du145 cells were infected with a total volume
of 100 µl of lenti-virus for 24-h. Cells that expressed the
targeted lentiviral shRNAs (shCDCA2-Du145) or scramble
control (shControl-Du145) were obtained by selecting the
infected cells with 1 mg/mL of puromycin for 3 to 4 weeks
at 37◦C.
Tumor Xenograft Assay
Animal experiments and maintenance were approved by the
Laboratory Animal Ethics Committee of Shenzhen University.
Twelve BALB/c nude mice (6 weeks old) were injected
subcutaneously with 2 × 106 shControl-Du145 or shCDCA2-
Du145 cells per animal. The body weight and tumor diameters
of the mice were measured every 3 or 4 days. Tumor size was
measured every other day with calipers, and tumor volumes were
calculated using a formula: volume = (width)2× length/2. All of
the infected mice were dissected 6 weeks later, and their tumors
were weighed.
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FIGURE 2 | CDCA2 is overexpressed in primary PCa and positively correlated with poor prognosis in patients with PCa. (A) Representative images of CDCA2 IHC
staining in normal prostate tissues and prostate cancer tissues. (B) Expression level of CDCA2 in TCGA prostate cancer study. Figure was cited from Ualcan. P =
0.0001. (C) Expression level of CDCA2 for different GS score cohorts in TCGA prostate cancer study. Figures were cited from Ualcan. **P < 0.01. (D) Expression
levels of CDCA2 in some prostate cancer studies in Oncomine database. P-value was as indicated.
Oncomine Analysis
Two Oncomine prostate-cancer-related microarray databases
were used in the expression profile, and the CDCA2 expression
profile in PCa was further validated in an Oncomine cancer
microarray database (http://www.oncomine.com) (22). Two
representative data groups were established (with more than
2-fold CDCA2 changes).
The Cancer Genome Atlas (TCGA) Data
Analysis
The expression levels of the CDCA family in PCa were analyzed
using TCGA data. We searched Ualcan, which is an online portal
TABLE 1 | Expression of cdca2 in BPH and PCa tissues.
Type No. of patients Scores for cdca2 signal P-value
Low expression High expression
– + ++ + + +
PCa 90 5 33 33 19 0.0001
BPH 90 15 53 15 7
for facilitating tumor subgroup gene expression based on TGCA
data (Ualcan: http://ualcan.path.uab.edu/) (23). Their expression
in normal and primary PCa tumors, and their expression based
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TABLE 2 | Relationship between clinicopathological variables and CDCA2
expression level in PCa patients.
Classification No. of patients CDCA2 signal P-value
– + ++ + + +
Age (years) 0.9020
>70 49 3 19 18 9
≤70 41 2 14 15 10
Gleason score 0.0392
≤6 39 3 16 15 5
7 23 2 9 7 5
≥8 28 0 8 11 9
Recurrence 0.5110
Yes 27 2 8 0 7
No 63 3 25 23 12
on the Gleason score (GS) was analyzed. In addition, we also
analyzed the expression and prognosis information of CDCA2
in all other cancer types listed at Ualcan. CDCA2 genomic copy
numbers in cancers was cited from TCGA Copy Number Portal
(http://portals.broadinstitute.org/tcga/home) (24).
Gene Expression Omnibus (GEO) Dataset
Analysis
A set of ChIP-Sequencing and RNA-Sequencing datasets
were downloaded from GEO. These included a hypoxia-
related ChIP-Sequencing and RNA-Sequencing dataset in PCa
PC3 cells (GSE106305) (25), a microarray for hypoxia- and
normoxia-treated PCa PC3 cells (GSE53012 and GSE80657)
(26, 27), a microarray for hypoxia- and normoxia-treated
lung cancer A549 cells (GSE48134)(28), a microarray for
HIF-1α inhibitor (echinomycin)-treated glioma U251 cells
(GSE7835) (29), a microarray for HIF-1α knockdown
breast cancer MCF7 cells (GSE3188), and a MEN1 ChIP-
Sequencing dataset in prostate cancer (GSE132827) (30, 31).
The method for ChIP-Sequencing data analysis was described
before (32).
Patient Samples and IHC
All benign prostatic hyperplasia (BPH) and PCa specimens
were collected with the patients’ consent in Shenzhen
People’s Hospital. The patients’ tissues were fixed in 10
% buffered formalin and embedded in paraffin. CDCA2
antibody (abcam) was used for IHC staining of tissue samples.
The IHC staining was performed as described previously
(33). According to the 2010 AJCC Cancer Staging Manual
seventh edition, tumor staging and differentiation of PCa
was defined as 1) Well differentiation:Gleason Score ≤
6; 2) Moderate differentiation: Gleason Score = 7; and
3) Poor differentiation:Gleason Score ≥ 8. Association
between CDCA2 expression and clinicopathological
characteristics were analyzed by Chi-squared and Fisher’s
exact test.
Statistical Analysis
All data in this paper are presented asmean± standard deviation.
Statistical assessments were carried out using Student’s t-test or
one-way anova. P< 0.05 was considered statistically significant.
RESULTS
The Cell Division Cycle Associated Protein
Family Is Increased in Prostate Cancer
In order to identify differential expression in PCa, we used
RNA-Sequencing to test the mRNA levels of Pca cell lines and
normal prostate tissue. A series of Pca cell lines (LAPC4, 22RV1,
LNCap, Du145, and PC3) were used in this study. The RNA
of normal prostate tissue was used as a control. We compared
the average expression levels in prostate cancer cells and normal
prostate tissues (GEO accession number:GSE148544). The RNA
sequencing data showed that genes coding for the cell division
cycle associated protein (CDCA) family that contains CDCA1 to
CDCA5 are upregulated in prostate cancer cell lines with different
increasing levels (Figure 1A). The overexpression and oncogenic
roles of CDCA family have been reported in several types of
tumors but not in PCa. We then performed a quantitative Real-
time PCR to verify the mRNA expression of some representative
CDCA members: CDCA1 to CDCA5 (Figures 1B–F). Consistent
with our RNA-sequencing results, the mRNA levels of CDCA1 to
CDCA5 increased in most of PCa cell lines.
Among our identified CDCA family members, CDCA2 is a
well-studied gene involved in cell division. It is necessary for
the establishment of heterochromatin in post-mitotic cells, and
it is also required for nuclear envelope reassembly during mitotic
exit (19, 20, 34). Previous studies also suggested that CDCA2 was
overexpressed in neuroblastoma, lung cancer, and oral squamous
cell carcinoma (5, 35, 36), but few reports are related to CDCA2
function in PCa. Here, we chose to study CDCA2 further in PCa.
CDCA2 Is Overexpressed in Primary PCa
and Positively Correlated With Poor
Prognosis in Patients With PCa
To further confirm the overexpression of CDCA2 in PCa, we
checked the protein levels in primary PCa patients’ samples.
Ninety BPH and 90 PCa tumor samples were collected in
Shenzhen Peoples’ Hospital. CDCA2 antibody was used for
immunohistochemistry (IHC) staining. The IHC staining results
showed that CDCA2 was overexpressed in the prostate cancer
tissues (Figure 2A). Our data indicated that CDCA2 was highly
expressed in 58% (52/90) of PCa tumor samples but with only
24% (22/90) frequency in BPH (p= 0.0001) (Table 1).We further
found that 63% (19/39) of patients with a Gleason Score (GS)≤ 6
showed lower CDCA2 expression and 71% (20/28) of men with
a GS of 8–10 displayed higher CDCA2 expression (P = 0.0392,
Table 2). Our results indicated that the overexpression of CDCA2
was negatively correlated with PCa progression.
We searched other groups’ finding to further support our
results. When compared with normal tissues, the mRNA levels
of CDCA2 was significantly increased in patients with PCa,
as found in a TCGA dataset provided by Ualcan (Figure 2B),
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FIGURE 3 | Knockdown of CDCA2 inhibits proliferation and induces apoptosis in PCa cell lines. (A) Knockdown efficacy of CDCA2 siRNA in Du145 and PC3 prostate
cancer cell lines. **P < 0.01. (B) Growth curve of Du145 for CDCA2 knockdown cells. *P < 0.05 and**P < 0.01. (C) Growth curve of PC3 for CDCA2 knockdown
cells. **P < 0.01. (D) Representative figures of flow cytometry for apoptosis study. (E) Statistical results for apoptosis study in Du145 and PC3 cell lines. (F) Western
blot for total PARP-1 level changes in Du145 and PC3 cells with CDCA2 inhibition by siRNA. All the data are shown as mean ± SD and **P < 0.01. All experiments
were repeated for three times.
and its expression was significantly positively correlated with
GS except GS = 10, which is not surprising since the patient
number of GS = 10 is too small (n = 4) (Figure 2C). We
further examined the expression of CDCA2 in other cancer
types. In all 33 TCGA cancer types, 18 of them exhibited
significantly higher CDCA2 expression (Supplemental Table 2).
And the number of cancer types is expected to be more than 18
since numbers of normal control are too small for some cancer
types to get significant biostatical analysis. What is more, higher
CDCA2 expression was correlated to patients’ survival in some
cancer types, such as in lung adenocarcinoma (LAUD), Kidney
renal papillary carcinoma (KIRP), and (liver hepatocellular
carcinoma) LIHC (Supplemental Figure 1). Besides TCGA data,
we also investigated the Oncomine database for two particular
studies and found that CDCA2 was increased in primary PCa
by about 2.899-fold in Varambally’s study and 1.889-fold in
Grasso’s study, when compared to a normal prostate gland
(37, 38)(Figure 2D). All data clearly indicated that CDCA2 was
overexpressed in PCa and is a candidate oncogene for PCa and
multiple other cancers.
Inhibition of CDCA2 Arrests Proliferation
and Induces Apoptosis in PCa Cell Lines
Our data—shown above—indicates that CDCA2 is a potential
oncogene in PCa. To explore the function of CDCA2 in PCa, we
adopted a small interfering RNA (siRNA) to knockdown CDCA2
and examined the effect of CDCA2 on cellular proliferation.
Du145 and PC3 were chosen for functional study since they have
higher CDCA2 expression. Firstly, we checked the knockdown
efficacy after 48-h transfection with siRNA. Quantitative Real-
time PCR analysis showed that the knockdown efficacy was
75 and 79% in Du145 and PC3, respectively (Figure 3A).
We counted the cell numbers after transfection and found
that cellular proliferation rate was lower in CDCA2 silenced
cells (Figures 3B,C).
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FIGURE 4 | Identification of differentially expressed genes in Du145 cells upon CDCA2 repression. (A) Heatmap of RNA- sequencing results for CDCA2 knockdown
Du145 cells. (B) Pathways affected by CDCA2 suppression were identified by KEGG pathways analysis. (C,D) Real-time PCR for some selected genes in Du145 and
PC3 cells. All the data are shown as mean ± SD and **P < 0.01. All experiments were repeated for three times.
We further examined the effect of CDCA2 on apoptosis.
Cells were stained with Annexin V-PE/7-AAD and analyzed by
flow cytometry after 48-h siRNA transfection. We found that
the inhibition of CDCA2 increased the apoptotic cell numbers
in Du145 and PC3 cells (Figures 3D,E). We also found that
loss of CDCA2 reduced protein level of PARP-1 (Figure 3F).
Collectively, our data indicate that CDCA2 plays a role in
regulating cellular proliferation and apoptosis, which contributes
to the tumorigenesis of PCa.
CDCA2 Regulates Genes Involved in
Cellular Proliferation and Apoptosis
In order to further investigate the mechanism of CDCA2
in cellular proliferation and apoptosis, we performed RNA
sequencing on CDCA2-silenced Du145 cells. About 2821 genes
were changed with a 2-fold difference found in CDCA2 silenced
cells (Figure 4A) (GEO accession number:GSE148544). KEGG
pathway analysis by online microarray analysis toolkit (https://
david.ncifcrf.gov/) indicated that loss of CDCA2 affects the
MAPK signaling pathway, ribosome biogenesis, Hippo pathway,
Jak-STAT pathway, and PI3K-Akt pathway (Figure 4B). Except
for this its role in signaling pathway, among the genes with 2-
fold changes, we found some well-reported tumor suppressor
genes were upregulated in CDCA2 knockdown cells, including
RASSF1, KISS1, PML, and GADD45A, as shown in Figure 4A.
We further confirmed the gene expression levels of these
genes by quantitative Real-time PCR both in Du145 and
PC3 cells. The expression of the potential targeted genes was
significantly increased after the inhibition of CDCA2, as shown
in Figures 4C,D. Thus, the alteration of oncogenic pathway and
upregulated tumor suppressors might play a role in induction of
apoptosis and inhibition of cellular proliferation when CDCA2
is repressed.
Inhibition of CDCA2 Suppresses Tumor
Growth in vivo
To further evaluate the function of CDCA2 in vivo, we
determined whether knockdown of CDCA2 could inhibit tumor
xenograft growth in nude mice. To this end, BALB/c nude mice
(6 weeks old) were injected subcutaneously with 2 × 106 of
Du145 shRNA scramble control (shControl-Du145) or CDCA2
knockdown cells (shCDCA2-Du145) permice andwere dissected
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FIGURE 5 | Inhibition of CDCA2 suppresses tumor growth in vivo. (A) Knockdown efficiency of CDCA2 shRNA stable cell line. (B) Representative images of the
tumors isolated from the mice. (C) Weight of tumors. (D) Tumor volume measured at different time points. (E) Body weight measured at different time points. (F,G)
Representative immunohistochemical staining images of Ki67 (F) and CDCA2 (G) in dissected tumor tissues. All the data are shown as mean ± SD.*P < 0.05 and **P
< 0.01.
6 weeks later. We found that knockdown of CDCA2 inhibited
tumor growth, leading to significantly reduced tumor volumes
(Figures 5A–C) and mass (Figure 5D) but not body weight
(Figure 5E). In addition, IHC staining for the proliferation
marker Ki67 revealed that expression of Ki67 was negatively
associated with CDCA2 in dissected tumor mass (Figures 5F,G),
indicating that CDCA2 repression led to inhibition of tumor cell
proliferation. Thus, our data demonstrated that knockdown of
CDCA2 inhibited tumor growth in vivo.
Overexpression of CDCA2 Was Not Caused
by Genomic Amplification
Our data has proved that CDCA2 was overexpressed in
PCa. We were interested in the mechanism of CDCA2
upregulation. We analyzed the TCGA dataset, which has the
genomic sequencing data for multiple cancer types. To our
surprise, no genomic amplification was found for CDCA2
in all 40 cancer types (TCGA Copy Number Portal, http://
portals.broadinstitute.org/tcga/home) (Figure 6A) (24). This
indicated that CDCA2 overexpression was controlled by
transcriptional regulation.
CDCA2 Was Induced in Hypoxic Condition
and Regulated by the HIF-1αPathway
To further elucidate the overexpression mechanism of CDCA2
in PCa, we analyzed some published ChIP-Sequencing and RNA-
Sequencing results. In a published ChIP-Sequencing and RNA-
Sequencing dataset (GSE106305), we found CDCA2 was elevated
in the hypoxia condition (Figure 6B). Hypoxia is strongly
associated with PCa progression (39, 40). Due to the rapid
growth of cancer cells in solid tumors, hypoxia often occurs
in tumors and can cause tumors to change and adapt to the
hypoxic condition. Overexpression of CDCA2 may be necessary
for proliferation and adaptation to hypoxia in solid tumors.
Beside this, we also found CDCA2 was repressed by
ONEUCT2 deficiency. It has been reported that ONEUCT2
drives tumor aggressiveness in neuroendocrine prostate
cancer (40), partially through regulating tumor hypoxia
and hypoxia signaling. Specifically, ONECUT2 activates
SMAD3, which regulates hypoxia signaling through moderating
HIF-1α transcriptional binding, causing higher degrees of
hypoxia in NEPC compared to prostate adenocarcinomas
(40). We found that CDCA2 was repressed at ONECUT2
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FIGURE 6 | CDCA2 was regulated by the hypoxia signaling pathway in prostate cancer. (A) Genomic amplification analysis of CDCA2 in TCGA datasets.
(B) RNA-Sequencing reading of CDCA2 in hypoxia and normoxia condition. (C) ChIP-Sequencing of HIF-1αon the promoter of CDCA2 at ONECUT2 deficiency.
(Continued)
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FIGURE 6 | (D) SMAD3 ChIP-Sequencing, HIF-1α ChIP-Sequencing, and SMAD3-HIF-1α ChIP-re-ChIP-Sequencing on promoter regions of CDCA2. (E) Mechanism
model of CDCA2 function and regulation in PCa. (F) CDCA2 array value in normoxia- and hypoxia-treated PC3 cells (GSE53012); (G) CDCA2 array value in normoxia-
and hypoxia-treated PC3 cells (GSE80657); (H) CDCA2 array value in normoxia- and hypoxia-treated lung cancer A549 cells (GSE48134); (I) CDCA2 array value in
HIF-1α inhibitor-enchinomycin-treated glioma U251 cells (GSE7835); (J) CDCA2 array value in HIF-1α knockdown breast cancer MCF7 cells (GSE3188). All the data
are shown as mean ± SD. *P < 0.05, **P < 0.01.
deficiency, and this could be explained by lower HIF-1α
binding to a CDCA2 promoter (Figures 6B,C). We further
found that SMAD3 binds to a CDCA2 promoter to recruit
HIF-1α, and its deficiency will lower HIF-1α binding on a
CDCA2 promoter region; this was evidenced by SMAD3
and HIF-1α ChIP-re-ChIP (Figure 6D). Our data indicated
that CDCA2 is a target of the hypoxia signaling pathway,
and it may regulate PCa tumorigenesis under the control
of HIF-1α/SMAD3 (Figure 6E). Regulation of CDCA2 by
HIF-1α was further supported by other published GEO
datasets. We found CDCA2 was increased in PCaPC3
cells (GSE53012 and GSE80657) or lung cancer A549 cells
(GSE48134) in the hypoxia condition (Figures 6F–H). In
addition, we found that inhibition of HIF-1α could reduce
CDCA2 expression. Echinomycin, which blocks the binding
of HIF-1α, repressed CDCA2 expression in glioma U251 cells
(GSE7835) (Figure 6I). Knockdown of HIF-1α caused CDCA2
mRNA levels to decline in breast cancer MCF7 cells (GSE3188)
(Figure 6J).
DISCUSSION
In our paper, we identified differential expression genes by
RNA-Sequencing in PCa and found the CDCA family to be
overexpressed in PCa cell lines and patients’ samples. Among
the CDCA family, we chose CDCA2 for further study. A serial
experiments and dataset analysis further confirmed that CDCA2
was upregulated in primary patients’ samples and positively
correlated with the patients’ clinical stage and poor progression
in prostate cancer. To our great interest, we found CDCA2
was not only overexpressed in PCa but also upregulated in
at least 18 cancer types in the TCGA dataset. What is more,
higher CDCA2 expression was correlated to patients’ survival
in some cancer types, such as in LAUD, KIRP, and LIHC.
We further demonstrated that CDCA2 was induced in hypoxia
and directly regulated by the HIF-1α/Smad3 complex. All these
suggested the potential oncogenic role of CDCA2 in PCa and
other tumors.
Here, we demonstrated that inhibition of CDCA2 induced
apoptosis and repressed cellular proliferation in vitro. Silencing
of CDCA2 also repressed tumor growth in vivo. As a member of
the CDCA family, CDCA2 has been reported to be oncogene in
several other tumors. Uchida et al found that CDCA2 prevented
the G1 phase arrest via decreasing the expression of CDKIs
and regulation of the DDR. Consistent with its function as
an oncogene in OSCCs, CDCA2 is frequently upregulated in
OSCCs, and overexpression of CDCA2 positively correlates
with high-stage OSCCs (5). Shi et al. found that CDCA2 is
widely overexpressed in lung adenocarcinoma (LAC), and a high
level of CDCA2 correlates with a worse prognosis (36). Feng
et al. found that CDCA2 was overexpressed in colon cancer
and promotes colon cancer cell proliferation and tumorigenesis,
probably through the PI3K/AKT pathway (41). Some studies
have suggested that CDCA2 and PP1γ form an essential complex
to recruit PP1 to chromatin, which is essential for cell growth and
cell viability (19, 42). Those reports further support our finding
about CDCA2 in PCa.
To elucidate CDCA2’s oncogenic role in PCa, we further
found that the loss of CDCA2 will increase the mRNA levels of
some tumor suppressor genes, including RASSF1, KISS1, PML,
and GADD45A. These tumor suppressor genes are involved in
cell proliferation regulation and apoptosis (43–46); our findings
will provide new insight for the mechanism of CDCA2 in
tumorigenesis in addition to its regulation of CDKIs.
Hypoxia, which will cause stress-induced oxidative DNA
damage, DNA strand breaks, and genetic aberrations, is
a common characteristic of all solid tumors. Cancer cells,
with serial genetic or epigenetic changes, can adapt to the
hypoxia condition by interacting some signaling pathway
(11, 47). Consequently, hypoxic tumor cells continue to
proliferate, become more invasive and are usually resistant to
radiotherapy and chemotherapy. The central component for
hypoxia stimulation is the HIF complex (11, 47). Through
exploring some public ChIP-Sequencing and RNA-Sequencing
datasets, we proved that CDCA2 was induced by hypoxia
condition and is involved in HIF1 signaling pathway and directly
controlled by HIF-1α and SMAD3 in PCa. It was reported that
HIF-1α and Smad3 interact directly and synergistically regulate
VEGF and endoglin expression (17, 18). This finding indicates
the potential important clinical significance of CDCA2 in PCa.
The regulation of CDCA2 under the hypoxia pathwaywas further
supported by other microarray GEO datasets, which were tested
in PCa, lung cancer, glioma, and breast cancer (26–30).
Besides the direct regulation by HIF-1α and SMAD3, through
some other public ChIP-Sequencing dataset, we also found that,
in PCa, CDCA2 was a directly regulated by MEN1, which
function as an oncogene in prostate cancer (GEO: GSE132827,
Supplemental Figure 2). This is another mechanism for CDCA2
expression and further validation for the fact that binding and a
new mechanism is needed in future.
CONCLUSIONS
In conclusion, our paper found that CDCA2 is overexpressed in
prostate cancer patients. It regulates cellular proliferation both in
vitro and in vivo and is a direct target of the hypoxia signaling
pathway in prostate cancer. Our data suggest that CDCA2 might
be a potential therapeutic biomarker for prostate cancer.
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